The research of the Alzheimer’s Disease Research Unit (ADRU) focuses on treatment, neuroimaging and genetic studies of Alzheimer's disease (AD) and healthy aging. Information for Alzheimer's patients and their families. Please consider making a secure online donation to support the Alzheimer's Disease Research Unit (ADRU).

The research of Dr. van Dyck and the Alzheimer’s Disease Research Unit (ADRU) focuses on treatment, neuroimaging and genetic studies of Alzheimer's disease (AD) and healthy aging.

Neuroimaging of Alzheimer’s Disease and Brain Aging. The current research focus of Dr. van Dyck and the Alzheimer’s Disease Research Unit (ADRU) is PET imaging of molecular targets of interest for Alzheimer’s disease across the full spectrum of disease from presymptomatic to symptomatic stages.

Christopher H. van Dyck (born 25 August 1955), is the Founder and Director of the Alzheimer's Disease Research Unit (ADRU) at Yale University School of Medicine, where he is Professor of Psychiatry, Neurology and Neuroscience.

2025年1月3日 · Dr. Christopher van Dyck, one of the world’s leading experts on the neurobiology and treatment of Alzheimer’s disease, was recently appointed the Elizabeth Mears and House Jameson Professor of Psychiatry.

Everyone is eligible to speak with ADRU specialists about issues concerning seniors, people with disabilities and their caregivers. There are various services and programs providing financial assistance. ADRU provides eligibility screenings and help completing applications. You may view the eligibility requirements (PDF).

Biogen announce appointment of Dominic Walsh as VP, and first head of the Alzheimer’s Disease & Dementia Research Unit (ADRU) Since 1992, his extensive work in Alzheimer’s disease research demonstrates the strategic vision, innovative thinking and tireless determination that made him a standout candidate for this role.

2025年3月13日 · Visit the Alzheimer's Disease Research Unit (ADRU) here. The purpose of this study is to assess the safety, tolerability and biomarker efficacy of Gantenerumab and Solanezumab in individuals who have an autosomal dominant Alzheimer's disease …

Dr. Christopher Vandyck, MD, is a Geriatric Medicine specialist practicing in New Haven, CT with 41 years of experience. including Medicare and Medicaid. New patients are welcome. Hospital...

Ryan O’Dell, MD, PhD, is a geriatric psychiatrist who specializes in the evaluation and management cognitive disorders, particularly Alzheimer’s disease. He says he was drawn to the field of Alzheimer’s disease and related dementias because there is …